Autoinflammatory and Autoimmune Disease
Professor Thomas Colletti, DHSc, MPAS, PA-C
The purpose of this article is to review the potential impact of anti-drug antibody (ADA) development on the safety and efficacy of biotherapeutics when treating autoinflammatory and autoimmune diseases. Awareness of ADAs can assist providers in making treatment decisions in their autoimmune and autoinflammatory patients, such as biotherapeutic drug or class switch.
Menefee EK. The Impact of Anti-Drug Antibody Development on the Efficacy and Safety of Biotherapeutics for the Treatment of Autoinflammatory and Autoimmune Disease States. Lynchburg Journal of Medical Science. 2021; 4(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.